Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 15, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

October 28, 2021

Conditions
SARS-CoV 2COVID-19
Interventions
DIETARY_SUPPLEMENT

5-ALA-Phosphate + SFC (5-ALA + SFC)

"Moderately ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) two times daily (resulting in 500 mg 5-ALA-Phosphate and 286.8 mg SFC (30.4 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days~Severely ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) three times daily (resulting in 750 mg 5-ALA-Phosphate and 430.2 mg SFC (45.6 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days"

Trial Locations (2)

Unknown

Bahrain Defense Force Royal Medical Services, Military Hospital, Manama

Salmaniya Medical Complex, Manama

All Listed Sponsors
collaborator

Bahrain Defence Force Hospital

OTHER

collaborator

Salmaniya Medical Complex

OTHER_GOV

lead

Royal College of Surgeons in Ireland - Medical University of Bahrain

OTHER

NCT04542850 - Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19 | Biotech Hunter | Biotech Hunter